We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Name | Symbol | Market | Type |
|---|---|---|---|
| GSK plc | NYSE:GSK | NYSE | Depository Receipt |
| Price Change | % Change | Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 0.245 | 0.61% | 40.105 | 40.195 | 39.855 | 40.02 | 2,299,572 | 19:09:26 |
From Jul 2019 to Jul 2024
By Adriano Marchese
GlaxoSmithKline PLC said Friday that the European Commission has granted conditional marketing authorization for Jemperli, a treatment for endometrial cancer.
The British pharmaceutical giant said the approval makes Jemperli, also known as dostarlimab, the first anti-PD-1 therapy available for endometrial cancer in Europe.
The drug is a treatment for patients with mismatch repair deficient recurrent or advanced endometrial cancer.
"Today's approval of dostarlimab means that for the first time in Europe, these women will have access to a new, innovative and much-needed therapy," Hal Barron, chief scientific officer and president of research and development, said.
Write to Adriano Marchese at adriano.marchese@wsj.com
(END) Dow Jones Newswires
April 23, 2021 10:30 ET (14:30 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year GSK Chart |
1 Month GSK Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
